Chromocell Therapeutics Total Revenue

Chromocell Therapeutics's total revenue stands at $43M as of June 2026. In the prior-year period, the figure was $0. That is below the sector sector average of $1.3B. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Chromocell Therapeutics reported $43M in total revenue versus $0 a year earlier. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Chromocell Therapeutics sits lower the its sector benchmark ($1.3B) with a total revenue of $43M. That is roughly 96.7% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

In the prior-year period, the figure was $0. Sustained growth in total revenue can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Chromocell Therapeutics's total revenue evolved across reporting periods, while the comparison chart places CHRO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.